Reported Sunday, Legend Biotech's LB2501 In Vivo CD19/CD20 Dual-Targeting CAR-T Achieves 100% ORR And 83.3% CR Rate At Dose Level 2 In Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

뉴스 본문을 불러오고 있어요.

Reported Sunday, Legend Biotech's LB2501 In Vivo CD19/CD20 Dual-Targeting CAR-T Achieves 100% ORR And 83.3% CR Rate At Dose Level 2 In Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | 웨이프 WAPE

Reported Sunday, Legend Biotech's LB2501 In Vivo CD19/CD20 Dual-Targeting CAR-T Achieves 100% ORR And 83.3% CR Rate At Dose Level 2 In Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

기사 요약

관련 종목

댓글 —